Daniel Rossi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Rossi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Bea Parcutela
Beckman Research Institute of the City of Hope 3 Department of Cancer Biology and Molecular Medicine Duarte, California
9 shared publications - Brenda Aguilar
City of Hope 1 Department of Hematology and Hematopoietic Cell Transplantation Duarte, California
9 shared publications - Cheng-Fu Kuo
Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
9 shared publications - Christine E. Brown
Department of Hematology & Hematopoietic Cell Transplantation (T Cell Therapeutics Research Laboratories), City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010, USA
9 shared publications - Darya Alizadeh
City of Hope 1 Department of Hematology and Hematopoietic Cell Transplantation Duarte, California
9 shared publications - Jeremy King
Beckman Research Institute of the City of Hope 3 Department of Cancer Biology and Molecular Medicine Duarte, California
9 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S1| Amino acid substitution for meCAR design and affinity characterization of meCAR variants.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S1| Amino acid substitution for meCAR design and affinity characterization of meCAR variants.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.See related Spotlight, p. 1536
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.See related Spotlight, p. 1536
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S5| Binding of meP-αCD20 on tumor triggers dual-targeting of HER2 meCAR T cells.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S5| Binding of meP-αCD20 on tumor triggers dual-targeting of HER2 meCAR T cells.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S6| Dual-targeting of HER2-meCAR T cells by meP-αPD-L1 and meP-αCD20.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S6| Dual-targeting of HER2-meCAR T cells by meP-αPD-L1 and meP-αCD20.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S7| Optimized meP-αCD20 Fab shows improved antitumor activity.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S7| Optimized meP-αCD20 Fab shows improved antitumor activity.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig.S4| meP-IL15s-mediated enrichment of meCAR T cells and assessment of toxicity.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig.S4| meP-IL15s-mediated enrichment of meCAR T cells and assessment of toxicity.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S3| Design and characterization of meditope-enabled CARs targeting additional antigens.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S3| Design and characterization of meditope-enabled CARs targeting additional antigens.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S2| in vivo efficacy of HER2 meCAR T cells in an OVCAR-3 xenograft model.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S2| in vivo efficacy of HER2 meCAR T cells in an OVCAR-3 xenograft model.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1553-1569
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies. See related Spotlight, p. 1536
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1553-1569
Open AccessMeditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies. See related Spotlight, p. 1536